CNSY Stock Catalyst: Plus Therapeutics Secures National Coverage Agreement with UnitedHealthcare for CNSide Assay

Sep 24, 2025 · 7:59pm ET

The agreement covers over 51 million people.

Max move

+70.4%

High of day $17.35

Sparker timei

7:59pm ET

CNSY · Sep 24, 2025

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Plus Therapeutics, Inc. (Nasdaq: PSTV) announced on September 25, 2025, a national coverage agreement with UnitedHealthcare Insurance Company (NYSE: UNH) for the CNSide Cerebrospinal Fluid Assay, designed for the detection of metastatic central nervous system (CNS) cancer.

The agreement extends coverage to over 51 million people under UnitedHealthcare's plans. The CNSide Assay is intended to aid in the diagnosis and management of metastatic CNS cancer by analyzing cerebrospinal fluid for the presence of cancer cells.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time CNSY sparks.

Download Sniper App →

Catch the next CNSY-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →